June 16, 2026
A Delaware federal judge on Tuesday upheld a jury's 2023 verdict finding that Guardant Health Inc. should pay TwinStrand Biosciences Inc. $83.4 million for willfully infringing diagnostic patents, refusing to overturn or enhance the award.
January 23, 2026
The Federal Circuit on Friday threw out a Patent Trial and Appeal Board decision finding Guardant Health couldn't show that a University of Washington DNA sequencing patent is invalid, sending the case back to the board for another look.
November 15, 2023
Guardant Health, a Silicon Valley cancer diagnostics startup run by ex-Illumina employees, said on Wednesday that it will appeal a patent infringement verdict of at least $83.4 million it lost a day earlier to a rival startup based in Seattle.